Take a Bow, Pharma, for the Hepatitis C Drugs
Reinke, T.
Managed Care 27(4): 12-13
2018
ISSN/ISBN: 1062-3388 PMID: 29701579 Document Number: 695875
The direct-acting virals revolutionized the treatment of hepatitis C. They also ushered turbocharged pricing. At least patients-and society-got a major health benefit in return.
Document emailed within 1 workday
Related Documents
Galloro, V. 2009: Mixing drugs. Latest pharma deals unlikely to affect prices: experts Modern Healthcare 39(11): 14Da Silva, L.C.; Mattar, E.; Carrilho, F.J.; Takeda, A.; Sette Júnior, H.; Gayotto, L.C. 1983: Disappearance of hepatitis B surface antigen in chronic type B hepatitis after clinical and laboratorial relapse produced by abrupt withdrawal of immunosuppressive drugs Revista do Instituto de Medicina Tropical de Sao Paulo 25(6): 270-274
Soriano, V.; Madejon, A.; Vispo, E.; Labarga, P.; Garcia-Samaniego, J.; Martin-Carbonero, L.; Sheldon, J.; Bottecchia, M.; Tuma, P.; Barreiro, P. 2008: Emerging drugs for hepatitis C Expert Opinion on Emerging Drugs 13(1): 1-19
Borges, W. 2002: Pharma-lary Texas Medicine 98(1): 32-36
Baekelandt, M. 2002: Irofulven (MGi Pharma) Current Opinion in Investigational Drugs 3(10): 1517-1526
Van Way, C.W. 2019: Bashing Big Pharma Missouri Medicine 116(2): 80-82
Kaplan, M.J. 2001: Leflunomide Aventis Pharma Current Opinion in Investigational Drugs 2(2): 222-230
Mucke, H.A.M. 2003: Rotigotine Schwarz Pharma Idrugs: the Investigational Drugs Journal 6(9): 894-899
2007: Most docs break bread with pharma Managed Care 16(5): 15
Piérard-Franchimont, C.; Arrese, J.E.; Piérard, G.E. 1996: Pharma-clinics. how i treat... rosacea Revue Medicale de Liege 51(6): 393-395
Nau, J.-Y. 2009: The experts and Big Pharma, the minister and his guru Revue Medicale Suisse 5(225): 2298
Bourla, A.; Johnson, S.R. 2015: Pharma 'could have done a better job' explaining drug costs Modern Healthcare 45(50): 30-31
Adler, D. 2006: Pharma tackles patient adherence Managed Care 15(9): 34-36
Payeras Cifre, A.; Socías Moyá, M.; Forteza-Rei Borralleras, J.; Besalduch Vidal, J. 1992: Hepatitis C viral infection and the consumption of intravenous drugs Revista de Sanidad E Higiene Publica 66(3-4): 233-237
Kulbertus, H.; Melon, P. 1999: Pharma-clinics. how i treat vasovagal syncope Revue Medicale de Liege 54(6): 510-513
Cahn, L. 2012: How to combat Pharma's costly coupon programs Managed Care 21(5): 22-26
Calinas-Correia, J. 2013: Big pharma: a story of success in a market economy Medicine Health Care and Philosophy 16(2): 305-309
Geenen, V. 2002: Pharma clinics how i treat ... autoimmune thyroiditis Revue Medicale de Liege 57(9): 567-570
Oldershausen v, H.F. 1976: Hepatitis-like liver disorders caused by infections, poisoning and drugs Verhandlungen der Deutschen Gesellschaft für Innere Medizin 82 Pt 1: 106-133
Walsh, N.; Verster, A.; Rodolph, M.; Akl, E.A. 2014: WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs International Journal on Drug Policy 25(3): 363-371